Crispr Therapeutics AG (CRSP)
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
It won't be able to be profitable without hitting its targets for both of these figures.
CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?
On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.
Crispr Therapeutics: Poised For A Major Turnaround
Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex Pharmaceuticals has provided significant financial support, experienced leadership, and validation, positioning Crispr for long-term success in the gene-editing space. Crispr's shares are currently undervalued, offering a strong buy opportunity below $50, with incoming revenue from Casgevy and a promising drug pipeline.
The Ultimate Biotech Stock to Buy With $50 Right Now
This company might be worth far more than many realize.
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $47.36, representing a -1.23% change from its previous close.
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $48.51, indicating a -0.84% shift from the previous trading day.
Wall Street Analysts See a 67.54% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 67.5% in CRISPR Therapeutics (CRSP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $48.05, representing a +0.47% change from its previous close.
Is CRISPR Therapeutics Stock a Buy?
The markets this biotech is looking to enter could be extremely lucrative.
2 Biotech Stocks That Are Screaming Buys This Month
They won't remain southbound forever.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $45.20, marking a -0.64% move from the previous day.
This Healthcare Growth Stock Could Be a Steal of a Deal Right Now
CRISPR Therapeutics is trading around multiyear lows.
